OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
DXR$10.5058

Daxor Corp

Closed End FundsVerified

Daxor Corp maintains a strong capital structure with a debt-to-equity ratio of 0.0, indicating no long-term debt obligations. The company's liquidity position is characterized by a low risk profile, with total liabilities amounting to $122,600 and total equity of $45,887,270. The price-to-book ratio of 1.33 and price-to-tangible-book ratio of 1.33 suggest that the company is trading at a slight premium to its book value. In terms of profitability, Daxor Corp's return on equity (ROE) of 19.98% and return on assets (ROA) of 19.93% are significantly higher than the typical benchmarks for closed-end funds, indicating strong returns relative to its equity and asset base. However, the company reported a net income of $9,169,770 despite a negative gross profit of -$1,045,510 and operating income of -$1,122,950, suggesting that non-operational gains or other income sources are contributing to its profitability. Daxor Corp's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segment and geographic diversification may expose the company to higher concentration risk, particularly if its primary revenue source experiences volatility. The company's growth trajectory is not clearly defined in the available data, as there are no specific revenue growth projections or historical growth rates provided. Analysts have assigned a mean price target of $22.50, with a median of $22.50 and a high of $23.00, indicating a consensus for a significant increase in the stock price. However, the mean recommendation of 2.00 (on a scale from 1 to 5) suggests a "Buy" rating, with no strong buy recommendations reported. Daxor Corp's risk assessment indicates a low probability of dilution and no immediate filing-based liquidity or dilution flags. The company's capital structure is not expected to be significantly impacted by dilution in the near term, and there are no recent events or filings that suggest a need for additional capital raising. Recent events and filings do not indicate any material changes in the company's operations or financial position. The company's operating cash flow of $570,940 suggests that it is generating positive cash from operations, which supports its liquidity position.

30-day price · DXR-0.19 (-1.9%)
Low$8.56High$12.31Close$9.95As of10 May, 00:00 UTC
Profile
CompanyDaxor Corp
TickerDXR.O
SectorFinancials
BusinessCollective Investments
Industry groupCollective Investments
IndustryClosed End Funds
AI analysis

Business. Daxor Corp is a closed-end fund that provides investment products and services to institutional and individual investors, primarily through its collective investment vehicles.

Classification. Daxor Corp is classified under the Financials sector, specifically in the Collective Investments business sector, with a high confidence level of 0.92.

Daxor Corp maintains a strong capital structure with a debt-to-equity ratio of 0.0, indicating no long-term debt obligations. The company's liquidity position is characterized by a low risk profile, with total liabilities amounting to $122,600 and total equity of $45,887,270. The price-to-book ratio of 1.33 and price-to-tangible-book ratio of 1.33 suggest that the company is trading at a slight premium to its book value. In terms of profitability, Daxor Corp's return on equity (ROE) of 19.98% and return on assets (ROA) of 19.93% are significantly higher than the typical benchmarks for closed-end funds, indicating strong returns relative to its equity and asset base. However, the company reported a net income of $9,169,770 despite a negative gross profit of -$1,045,510 and operating income of -$1,122,950, suggesting that non-operational gains or other income sources are contributing to its profitability. Daxor Corp's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segment and geographic diversification may expose the company to higher concentration risk, particularly if its primary revenue source experiences volatility. The company's growth trajectory is not clearly defined in the available data, as there are no specific revenue growth projections or historical growth rates provided. Analysts have assigned a mean price target of $22.50, with a median of $22.50 and a high of $23.00, indicating a consensus for a significant increase in the stock price. However, the mean recommendation of 2.00 (on a scale from 1 to 5) suggests a "Buy" rating, with no strong buy recommendations reported. Daxor Corp's risk assessment indicates a low probability of dilution and no immediate filing-based liquidity or dilution flags. The company's capital structure is not expected to be significantly impacted by dilution in the near term, and there are no recent events or filings that suggest a need for additional capital raising. Recent events and filings do not indicate any material changes in the company's operations or financial position. The company's operating cash flow of $570,940 suggests that it is generating positive cash from operations, which supports its liquidity position.
Key takeaways
  • Daxor Corp has a strong capital structure with no long-term debt and a low debt-to-equity ratio.
  • The company's ROE and ROA are significantly higher than typical benchmarks for closed-end funds.
  • Daxor Corp's revenue is concentrated in a single business segment, which may increase its exposure to concentration risk.
  • Analysts have assigned a "Buy" rating to the stock, with a mean price target of $22.50.
  • The company's liquidity position is strong, with no immediate dilution or liquidity flags detected.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$26.7k
Gross profit-$1.0M
Operating income-$1.1M
Net income$9.2M
R&D
SG&A
D&A
SBC
Operating cash flow$570.9k
CapEx
Free cash flow
Total assets$46.0M
Total liabilities$122.6k
Total equity$45.9M
Cash & equivalents
Long-term debt$0.00
Valuation
Market price$10.50
Market cap$61.2M
Enterprise value
P/E6.7
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B1.3
P/Tangible book1.3
Tangible book$45.9M
Net cash
Current ratio
Debt/Equity0.0
ROA19.9%
ROE20.0%
Cash conversion6.0%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Closed End Funds · cohort 5 companies
MetricDXRActivity
Op margin-4207.4%63.2% medp25 39.8% · p75 88.3%bottom quartile
Net margin34356.6%71.0% medp25 12.8% · p75 89.3%top quartile
Gross margin-3917.2%76.7% medp25 50.4% · p75 92.6%bottom quartile
CapEx / revenue-3.8% medp25 -7.7% · p75 -0.9%
Debt / equity0.0%1.5% medp25 0.0% · p75 68.2%bottom quartile
Observations
IR observations
Mean price target22.50 USD
Median price target22.50 USD
High price target23.00 USD
Low price target22.00 USD
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count2.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate-0.21 USD
Last actual EPS1.81 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-16 16:17 UTC#54a47cb3
Market quoteclose USD 9.66 · shares 0.01B diluted
no public URL
2026-05-16 16:19 UTC#8c9a8a49
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 19:40 UTCJob: 487bdb0f